Literature DB >> 7632816

FAB classification of myelodysplastic syndromes: merits and controversies.

G E Verhoef1, S Pittaluga, C De Wolf-Peeters, M A Boogaerts.   

Abstract

Guidelines for the definition and diagnosis of myelodysplasia were set out by the French-American-British Cooperative group (FAB), and the resulting framework has greatly helped the now very large number of workers in many scientific disciplines who are actively investigating the myelodysplastic syndromes (MDS). Most patients with MDS can be readily classified into clinically relevant subgroups by correlation of clinical findings with the findings from well-prepared peripheral blood and bone marrow specimens. However, there are several areas where the standard morphological features are insensitive, but integration of these parameters with histology and cytogenetic and molecular techniques may help us in understanding this fascinating disease.

Entities:  

Mesh:

Year:  1995        PMID: 7632816     DOI: 10.1007/bf01696227

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  65 in total

Review 1.  Leukaemia Research Fund annual guest lecture 1990. Genetics lesions in preleukaemia.

Authors:  A Jacobs
Journal:  Leukemia       Date:  1991-04       Impact factor: 11.528

2.  Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia.

Authors:  J Anastasi; J W Vardiman; R Rudinsky; M Patel; J Nachman; C M Rubin; M M Le Beau
Journal:  Blood       Date:  1991-06-01       Impact factor: 22.113

3.  Clinical and cytogenetic characteristics of myelodysplastic syndromes developing myelofibrosis.

Authors:  K Ohyashiki; I Sasao; J H Ohyashiki; T Murakami; A Iwabuchi; T Tauchi; M Saito; S Nakazawa; H Serizawa; Y Ebihara
Journal:  Cancer       Date:  1991-07-01       Impact factor: 6.860

4.  Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin.

Authors:  J W Janssen; M Buschle; M Layton; H G Drexler; J Lyons; H van den Berghe; H Heimpel; B Kubanek; E Kleihauer; G J Mufti
Journal:  Blood       Date:  1989-01       Impact factor: 22.113

5.  Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia.

Authors:  K Tobal; A Pagliuca; B Bhatt; N Bailey; D M Layton; G J Mufti
Journal:  Leukemia       Date:  1990-07       Impact factor: 11.528

6.  Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.

Authors:  S Suciu; R Kuse; H J Weh; D K Hossfeld
Journal:  Cancer Genet Cytogenet       Date:  1990-01

7.  Myelodysplastic syndromes: a study of 101 cases according to the FAB classification.

Authors:  T Vallespi; M Torrabadella; A Julia; D Irriguible; A Jaen; G Acebedo; J Triginer
Journal:  Br J Haematol       Date:  1985-09       Impact factor: 6.998

8.  Monosomy 7 in granulocytes and monocytes in myelodysplastic syndrome.

Authors:  J Kere; T Ruutu; A de la Chapelle
Journal:  N Engl J Med       Date:  1987-02-26       Impact factor: 91.245

9.  Prognostic implications of bone marrow culturing in myelodysplastic syndrome: a retrospective analysis.

Authors:  R Raymakers; F Preijers; J Boezeman; E Rutten; T De Witte
Journal:  Leuk Lymphoma       Date:  1994-06

10.  Mechanisms of ras mutation in myelodysplastic syndrome.

Authors:  J J Yunis; A J Boot; M G Mayer; J L Bos
Journal:  Oncogene       Date:  1989-05       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.